<DOC>
	<DOCNO>NCT01159522</DOCNO>
	<brief_summary>The goal study SCB01A determine Maximum Tolerated Dose SCB01A patient advance solid tumor fail previous therapy .</brief_summary>
	<brief_title>A Dose Escalation Study SCB01A Subjects With Advanced Solid Tumors Who Have Failed Standard Therapy</brief_title>
	<detailed_description>This open-label , single-arm , dose-escalation , safety tolerability study . Eligible subject assign SCB01A dose level time study entry schedule receive two treatment cycle SCB01A observation DLT . A treatment cycle define three-hour infusion SCB01A give every 21 day . Unless off-study criterion meet , study period subject two cycle .</detailed_description>
	<criteria>1 . Subjects least 18 year age . 2 . Have provide write informed consent prior initiation study procedure . 3 . Have histologically cytologically confirm diagnosis advance solid tumor fail respond available standard treatment . 4 . Have ECOG PS scale 01 time enrollment . 5 . Have adequate organ function : 1 . Bone marrow function : White blood cell count ( WBC ) ≥ 4000/μL Absolute neutrophil count ( ANC ) ≥ 1500/μL Hemoglobin ≥ 10.0 g/dL Platelet count ≥ 100,000/μL 2 . Hepatic Function : Serum total bilirubin level ≤ 1.0 x upper normal limit Serum alanine aminotransferase ( ALT ) level ≤ 2.5 x upper normal limit 3 . Renal Function : • Serum creatinine ≤ 1.0 x upper normal limit creatinine clearance ( estimate CockcroftGault formula ) &gt; 60 mL/min 4 . Heart Function : Ejection fraction ≥ 55 % QTC &lt; 450 msec 6 . Have life expectancy least 3 month 7 . Have negative serum pregnancy test within 1 week study drug administration ( woman childbearing potential diagnosed germ cell tumor betaHCG ) . 8 . Are willing practice medically accept contraception ( risk contraception exists ) throughout study period ( screen Final Visit ) . 1 . Subjects fail recover prior anticancer treatmentrelated toxicity , e.g . surgery , chemotherapy , radiotherapy , target therapy , biologic therapy , immunotherapy , alternative medicine , hormonal therapy , investigational agent ( ) . 2 . Treatment investigational drug , chemotherapy , target agent ( ) , biologic therapy ( e.g. , IL2 , Interferon , etc . ) , immunotherapy ( e.g . tumor vaccine , etc . ) , alternative medicine hormonal therapy ( e.g . antiestrogens , antiandrogens , etc . ) , radiation ( except bone ) surgery ( except exploratory biopsy intravenous device implantation , etc . ) within 28 day prior study entry . 3 . Grade 2 high sensory neuropathy etiology . 4 . Subjects severe cardiopulmonary disease ( include history stable , effortinduced unstable angina pectoris , myocardial infarction , arrhythmia ) systemic diseases poor control . 5 . Females pregnant , lactating , positive serum pregnancy test except diagnosed germ cell tumor betaHCG prior study treatment . Premenopausal woman abstinent must prove surgical sterility compliance contraceptive regimen . Male subject male partner female subject must abstinent , surgically sterile , utilizing barrier contraceptive method . 6 . Tumor central nervous system ( CNS ) involvement . 7 . Subjects concomitant active 2nd primary malignancy diseasefree 3 year follow definitive therapy prior metachronous malignancy , except surgically cure carcinoma , i.e . situ cervix adequately treat basal cell carcinoma skin Dukes ' A colorectal cancer . 8 . Known history allergy component investigational preparation . 9 . History exposure SCB01A analog . 10 . Active infection require antibiotic therapy time study entry . 11 . Is unwilling unable comply protocol requirement . 12 . Known human immunodeficiency virus ( HIV ) infection . 13 . History receive organ transplantation immunologic illness require continuous immunosuppressant agent therapy . 14 . Have medical psychological condition would permit study participant complete study sign inform consent . 15 . Have disease , dysfunction , alcohol drug abuse , physical examination lab finding , investigator 's opinion , would exclude subject study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>Advanced Solid Tumors Who Have Failed Standard Therapy</keyword>
</DOC>